Company intelligence / Profile preview

MidAmerica Pharmaceuticals

Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

MidAmerica Pharmaceuticals was a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products, primarily in the cardiovascular therapeutic area. The company's portfolio was anchored by the Procardia (nifedipine) line of calcium channel blockers, which it acquired from Pfizer. MidAmerica aimed to maximize the value of established brands through targeted marketing and lifecycle management. While the company was active in the early 2000s, it is no longer operating as an independent entity.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Pfizer

Beyond the preview

Go deeper on MidAmerica Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MidAmerica Pharmaceuticals.

Explore the full profile